Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases
The intestinal microbiota is a dynamic community of bacteria, fungi, and viruses that mediates mucosal homeostasis and physiology. Imbalances in the microbiome and aberrant immune responses to gut bacteria can disrupt homeostasis and are associated with inflammatory bowel diseases (IBDs) in humans a...
Gespeichert in:
| Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2019-06, Vol.156 (8), p.2174-2189 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2189 |
|---|---|
| container_issue | 8 |
| container_start_page | 2174 |
| container_title | Gastroenterology (New York, N.Y. 1943) |
| container_volume | 156 |
| creator | Cohen, Louis J. Cho, Judy H. Gevers, Dirk Chu, Hiutung |
| description | The intestinal microbiota is a dynamic community of bacteria, fungi, and viruses that mediates mucosal homeostasis and physiology. Imbalances in the microbiome and aberrant immune responses to gut bacteria can disrupt homeostasis and are associated with inflammatory bowel diseases (IBDs) in humans and colitis in mice. We review genetic variants associated with IBD and their effects on the intestinal microbiome, the immune response, and disease pathogenesis. The intestinal microbiome, which includes microbial antigens, adjuvants, and metabolic products, affects the development and function of the intestinal mucosa, influencing inflammatory responses in the gut. Therefore, strategies to manipulate the microbiome might be used in treatment of IBD. We review microbe-based therapies for IBD and the potential to engineer patients’ intestinal microbiota. We discuss how studies of patients with IBD and mouse models have advanced our understanding of the interactions between genetic factors and the gut microbiome, and challenges to the development of microbe-based therapies for IBD. |
| doi_str_mv | 10.1053/j.gastro.2019.03.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6568267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0016508519335590</els_id><sourcerecordid>2193622879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-47669dd9828a36980fb90e18b83c41149c33c16cde3c9404be28ec40a66a9693</originalsourceid><addsrcrecordid>eNp9kUFvEzEQhS0EoqHwDxDykcsuY3vXsS9ItKWhUhGX3C2vd7ZxtLsOthNUfj2OEgpcOM1hZt6beR8hbxnUDFrxYVs_2JRjqDkwXYOogS2fkQVruaoAGH9OFqXIqgXVXpBXKW0BQAvFXpILAUoBcL4gP1c4Y_aO3lqXQ0zUzj3NG6R3c8aU_WxH-tW7GDofJqSrve-R3uABx7CbcM40DOc-Vlc2YU_XG4x25zHRIcQiM4x2mmzRfqRX4QeO9MYnLJPpNXkx2DHhm3O9JOvbz-vrL9X9t9Xd9af7yjVS5KpZSqn7XiuurJBawdBpQKY6JVzDWKOdEI5J16NwuoGmQ67QNWCltFpqcUk-nmR3-27C3pWjox3NLvrJxkcTrDf_dma_MQ_hYGQrFZfLIvD-LBDD930JxUw-ORxHO2PYJ8OZFpJztTx6NafREkhKEYcnGwbmSM1szYmaOVIzIEyhVtbe_X3i09JvTH9-wJLTwWM0yXmcHfY-osumD_7_Dr8Aq5qtAg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2193622879</pqid></control><display><type>article</type><title>Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Cohen, Louis J. ; Cho, Judy H. ; Gevers, Dirk ; Chu, Hiutung</creator><creatorcontrib>Cohen, Louis J. ; Cho, Judy H. ; Gevers, Dirk ; Chu, Hiutung</creatorcontrib><description>The intestinal microbiota is a dynamic community of bacteria, fungi, and viruses that mediates mucosal homeostasis and physiology. Imbalances in the microbiome and aberrant immune responses to gut bacteria can disrupt homeostasis and are associated with inflammatory bowel diseases (IBDs) in humans and colitis in mice. We review genetic variants associated with IBD and their effects on the intestinal microbiome, the immune response, and disease pathogenesis. The intestinal microbiome, which includes microbial antigens, adjuvants, and metabolic products, affects the development and function of the intestinal mucosa, influencing inflammatory responses in the gut. Therefore, strategies to manipulate the microbiome might be used in treatment of IBD. We review microbe-based therapies for IBD and the potential to engineer patients’ intestinal microbiota. We discuss how studies of patients with IBD and mouse models have advanced our understanding of the interactions between genetic factors and the gut microbiome, and challenges to the development of microbe-based therapies for IBD.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1053/j.gastro.2019.03.017</identifier><identifier>PMID: 30880022</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Drugs, Investigational - administration & dosage ; Drugs, Investigational - pharmacology ; Gastrointestinal Microbiome - genetics ; Gastrointestinal Microbiome - immunology ; Genome, Human ; Host Genetics ; Humans ; Immunotherapy - methods ; Inflammatory Bowel Disease ; Inflammatory Bowel Diseases - microbiology ; Inflammatory Bowel Diseases - pathology ; Inflammatory Bowel Diseases - therapy ; Mice ; Microbiome ; Models, Animal ; Mucosal Immunity ; Practice Guidelines as Topic ; Preclinical Therapies ; Prognosis ; Treatment Outcome</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 2019-06, Vol.156 (8), p.2174-2189</ispartof><rights>2019 AGA Institute</rights><rights>Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-47669dd9828a36980fb90e18b83c41149c33c16cde3c9404be28ec40a66a9693</citedby><cites>FETCH-LOGICAL-c463t-47669dd9828a36980fb90e18b83c41149c33c16cde3c9404be28ec40a66a9693</cites><orcidid>0000-0003-1998-0363 ; 0000-0001-7489-0446</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0016508519335590$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30880022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Louis J.</creatorcontrib><creatorcontrib>Cho, Judy H.</creatorcontrib><creatorcontrib>Gevers, Dirk</creatorcontrib><creatorcontrib>Chu, Hiutung</creatorcontrib><title>Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>The intestinal microbiota is a dynamic community of bacteria, fungi, and viruses that mediates mucosal homeostasis and physiology. Imbalances in the microbiome and aberrant immune responses to gut bacteria can disrupt homeostasis and are associated with inflammatory bowel diseases (IBDs) in humans and colitis in mice. We review genetic variants associated with IBD and their effects on the intestinal microbiome, the immune response, and disease pathogenesis. The intestinal microbiome, which includes microbial antigens, adjuvants, and metabolic products, affects the development and function of the intestinal mucosa, influencing inflammatory responses in the gut. Therefore, strategies to manipulate the microbiome might be used in treatment of IBD. We review microbe-based therapies for IBD and the potential to engineer patients’ intestinal microbiota. We discuss how studies of patients with IBD and mouse models have advanced our understanding of the interactions between genetic factors and the gut microbiome, and challenges to the development of microbe-based therapies for IBD.</description><subject>Animals</subject><subject>Drugs, Investigational - administration & dosage</subject><subject>Drugs, Investigational - pharmacology</subject><subject>Gastrointestinal Microbiome - genetics</subject><subject>Gastrointestinal Microbiome - immunology</subject><subject>Genome, Human</subject><subject>Host Genetics</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Inflammatory Bowel Disease</subject><subject>Inflammatory Bowel Diseases - microbiology</subject><subject>Inflammatory Bowel Diseases - pathology</subject><subject>Inflammatory Bowel Diseases - therapy</subject><subject>Mice</subject><subject>Microbiome</subject><subject>Models, Animal</subject><subject>Mucosal Immunity</subject><subject>Practice Guidelines as Topic</subject><subject>Preclinical Therapies</subject><subject>Prognosis</subject><subject>Treatment Outcome</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFvEzEQhS0EoqHwDxDykcsuY3vXsS9ItKWhUhGX3C2vd7ZxtLsOthNUfj2OEgpcOM1hZt6beR8hbxnUDFrxYVs_2JRjqDkwXYOogS2fkQVruaoAGH9OFqXIqgXVXpBXKW0BQAvFXpILAUoBcL4gP1c4Y_aO3lqXQ0zUzj3NG6R3c8aU_WxH-tW7GDofJqSrve-R3uABx7CbcM40DOc-Vlc2YU_XG4x25zHRIcQiM4x2mmzRfqRX4QeO9MYnLJPpNXkx2DHhm3O9JOvbz-vrL9X9t9Xd9af7yjVS5KpZSqn7XiuurJBawdBpQKY6JVzDWKOdEI5J16NwuoGmQ67QNWCltFpqcUk-nmR3-27C3pWjox3NLvrJxkcTrDf_dma_MQ_hYGQrFZfLIvD-LBDD930JxUw-ORxHO2PYJ8OZFpJztTx6NafREkhKEYcnGwbmSM1szYmaOVIzIEyhVtbe_X3i09JvTH9-wJLTwWM0yXmcHfY-osumD_7_Dr8Aq5qtAg</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Cohen, Louis J.</creator><creator>Cho, Judy H.</creator><creator>Gevers, Dirk</creator><creator>Chu, Hiutung</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1998-0363</orcidid><orcidid>https://orcid.org/0000-0001-7489-0446</orcidid></search><sort><creationdate>20190601</creationdate><title>Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases</title><author>Cohen, Louis J. ; Cho, Judy H. ; Gevers, Dirk ; Chu, Hiutung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-47669dd9828a36980fb90e18b83c41149c33c16cde3c9404be28ec40a66a9693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Drugs, Investigational - administration & dosage</topic><topic>Drugs, Investigational - pharmacology</topic><topic>Gastrointestinal Microbiome - genetics</topic><topic>Gastrointestinal Microbiome - immunology</topic><topic>Genome, Human</topic><topic>Host Genetics</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Inflammatory Bowel Disease</topic><topic>Inflammatory Bowel Diseases - microbiology</topic><topic>Inflammatory Bowel Diseases - pathology</topic><topic>Inflammatory Bowel Diseases - therapy</topic><topic>Mice</topic><topic>Microbiome</topic><topic>Models, Animal</topic><topic>Mucosal Immunity</topic><topic>Practice Guidelines as Topic</topic><topic>Preclinical Therapies</topic><topic>Prognosis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Louis J.</creatorcontrib><creatorcontrib>Cho, Judy H.</creatorcontrib><creatorcontrib>Gevers, Dirk</creatorcontrib><creatorcontrib>Chu, Hiutung</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Louis J.</au><au>Cho, Judy H.</au><au>Gevers, Dirk</au><au>Chu, Hiutung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>156</volume><issue>8</issue><spage>2174</spage><epage>2189</epage><pages>2174-2189</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><abstract>The intestinal microbiota is a dynamic community of bacteria, fungi, and viruses that mediates mucosal homeostasis and physiology. Imbalances in the microbiome and aberrant immune responses to gut bacteria can disrupt homeostasis and are associated with inflammatory bowel diseases (IBDs) in humans and colitis in mice. We review genetic variants associated with IBD and their effects on the intestinal microbiome, the immune response, and disease pathogenesis. The intestinal microbiome, which includes microbial antigens, adjuvants, and metabolic products, affects the development and function of the intestinal mucosa, influencing inflammatory responses in the gut. Therefore, strategies to manipulate the microbiome might be used in treatment of IBD. We review microbe-based therapies for IBD and the potential to engineer patients’ intestinal microbiota. We discuss how studies of patients with IBD and mouse models have advanced our understanding of the interactions between genetic factors and the gut microbiome, and challenges to the development of microbe-based therapies for IBD.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30880022</pmid><doi>10.1053/j.gastro.2019.03.017</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-1998-0363</orcidid><orcidid>https://orcid.org/0000-0001-7489-0446</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0016-5085 |
| ispartof | Gastroenterology (New York, N.Y. 1943), 2019-06, Vol.156 (8), p.2174-2189 |
| issn | 0016-5085 1528-0012 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6568267 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection |
| subjects | Animals Drugs, Investigational - administration & dosage Drugs, Investigational - pharmacology Gastrointestinal Microbiome - genetics Gastrointestinal Microbiome - immunology Genome, Human Host Genetics Humans Immunotherapy - methods Inflammatory Bowel Disease Inflammatory Bowel Diseases - microbiology Inflammatory Bowel Diseases - pathology Inflammatory Bowel Diseases - therapy Mice Microbiome Models, Animal Mucosal Immunity Practice Guidelines as Topic Preclinical Therapies Prognosis Treatment Outcome |
| title | Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T19%3A16%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20Factors%20and%20the%20Intestinal%20Microbiome%20Guide%20Development%20of%20Microbe-Based%20Therapies%20for%20Inflammatory%20Bowel%20Diseases&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Cohen,%20Louis%20J.&rft.date=2019-06-01&rft.volume=156&rft.issue=8&rft.spage=2174&rft.epage=2189&rft.pages=2174-2189&rft.issn=0016-5085&rft.eissn=1528-0012&rft_id=info:doi/10.1053/j.gastro.2019.03.017&rft_dat=%3Cproquest_pubme%3E2193622879%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2193622879&rft_id=info:pmid/30880022&rft_els_id=S0016508519335590&rfr_iscdi=true |